Letter to the Editor
Zolpidem use as a predictor of Parkinson's disease

https://doi.org/10.1016/j.jpsychires.2014.09.015Get rights and content

Section snippets

Role of funding source

This submission was unfunded.

Contributors

I am the sole contributor to this letter.

Conflict of interest

I have no conflicting interests with regard to the present submission.

Acknowledgements

I have no acknowledgements to declare.

References (2)

  • A. Raggi et al.

    Sleep disorders in Parkinson's disease: a narrative review of the literature

    Rev Neurosci

    (2013)
  • Y.W. Yang et al.

    Zolpidem and the risk of Parkinson's disease: a nationwide population-based study

    J Psychiatr Res

    (2014 Jul 25)

Cited by (3)

  • Sleep and affective disorders in relation to Parkinson's disease risk among older women from the Women's Health Initiative

    2022, Journal of Affective Disorders
    Citation Excerpt :

    Recent studies have also indicated that past experience with stressful life events as well as chronic stress may increase the likelihood of psychiatric disorders, such as depression and anxiety, which in turn can promote neurodegeneration and the development of PD through a variety of mechanisms which include repeated catecholamine release and reuptake and the formation of toxic dopamine metabolites (Dalle and Mabandla, 2018; Goldstein and Kopin, 2018; Jacob et al., 2010). Limited evidence suggests that psychiatric disorders, such as depression and anxiety, as well as psychotropic medications used to treat these disorders may be prodromal to the onset of PD motor symptoms (Andrade, 2015; Huang et al., 2015; Shadfar et al., 2018; Shamim et al., 2019; Zenesini et al., 2019). For instance, a meta-analysis of 15 studies indicated that prodromal depression might be associated with twice the risk of subsequent PD (Bareeqa et al., 2022).

  • Psychotropic medication use and Parkinson's disease risk amongst older women

    2022, Annals of Clinical and Translational Neurology
View full text